News

December 8, 2014

Cancer Active Immunotherapy OBI-822 Mechanelism Action

December 8, 2014

Introduction of OBI PHARMA, INC.’s

[…]
July 21, 2014

OBI Pharma Announces Completion of Patient Enrollment in Phase 2/Phase 3 Clinical Trial of OBI-822 Active Immunotherapy for Metastatic Breast Cancer

[…]
January 15, 2014

OBI Pharma, Inc. won Taiwan “Venture Capital Star” The Best Investment Award

[…]